Views & Analysis | Perspectives on pharma industry issues

R&D

Alzheimer's research is moving toward more selective targets

As we mark World Alzheimer’s Day, it is worth reflecting on the progress made in recent years.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access

From first approval to lasting value: What sets successful e...

Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.

Market Access

drug pricing in the UK, pills overlain on map

Request to look further into NICE non-submissions in the fut...

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

R&D

Changing Faces: Board of Director and Advisory Board hires, ...

Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.

Articles

External perspectives: key account management

In a new series where we hear from people who work within industries outside of pharma, we speak with Hajo Rapp on how Siemens has successfully implemented key account management. Last year, Siemens AG was recognised by the Strategic Account Management Association (SAMA) for its successful customer management...

Articles

Redefining the blockbuster model: Why the $1 billion entry p...

In the first of a two-part article, Sarah Rickwood questions how, with so many ‘blockbuster drugs’ we can truly define an outstanding pharmaceutical product. When Zantac® surpassed US$1 billion in annual sales in 1987, the first global “blockbuster” pharmaceutical product was born. Today...

Articles

Pharma news highlights: Novartis, J&J, Merck and more

It’s never quiet for too long in the pharma industry – Ed Silverman shares his top news highlights from the past four weeks, including Novartis’ manufacturing issues and J&J’s litigation settlement. In its quest to speed approvals and reward innovation, is the FDA green-lighting medicines with too...

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Sales & Marketing

Wooden pawns representing number of employees

Headcount is not a growth strategy

Deciding when, where, and how quickly to add headcount is rarely straightforward.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Digital

Changing Faces: Digital and supplier hires, August 2026

Digital health, clinical technology, contract services, and life sciences suppliers all saw notable leadership changes last month.

Market Access

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access